Hypoimmune cell engineering may enable scalable type 1 diabetes therapies without immunosuppression, advancing regenerative medicine approaches, according to Dr. Steve Harr, president and CEO of Sana Biotechnology.
Steve Harr
Advertisement
Steve Harr, MD is president and CEO of Sana Biotechnology.
Articles by Steve Harr
Advertisement
Latest Updated Articles
Advertisement
Advertisement